Bionano Genomics (BNGO) EBIT (2017 - 2026)

Bionano Genomics has disclosed EBIT across 10 years of filings, most recently posting -$7.9 million for Q1 2026.

• EBIT for Q1 2026 came in at -$7.9 million, up 6.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.8 million (down 3715.02% YoY), and the FY2025 annual result was -$33.3 million, down 41.77% from the prior year.
• EBIT came in at -$7.9 million for Q1 2026 at Bionano Genomics, up from -$8.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $68.5 million in Q4 2024 to a low of -$113.2 million in Q3 2023.
• The 5-year median for EBIT is -$29.9 million (2022), against an average of -$24.2 million.
• Across the five-year window, EBIT tumbled 252.15% in 2023 and soared 374.62% in 2024, its largest moves.
• Bionano Genomics' EBIT stood at -$37.5 million in 2022, then jumped by 33.51% to -$25.0 million in 2023, then jumped by 374.62% to $68.5 million in 2024, then slumped by 112.46% to -$8.5 million in 2025, then advanced by 7.49% to -$7.9 million in 2026.
• The last three EBIT figures came in at -$7.9 million (Q1 2026), -$8.5 million (Q4 2025), and -$8.5 million (Q3 2025), per Business Quant data.